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Objective: To deliver 2,3,5,6-tetramethylpyrazine (TMP) in a relatively large dose through 
a transdermal route and facilitate the practical application of microemulison in transdermal 
drug delivery.
Methods: The pseudo-ternary phase diagram for microemulsion regions was constructed 
using isopropyl myristate as oil phase, Labrasol® as surfactant, and Plurol® Oleique CC 497 as 
cosurfactant. A uniform experimental design was applied for formulation optimization. In vitro 
skin permeation experiments of six formulations were undertaken with TMP transdermal patch 
(EUDRAGIT® E100 as matrix) and TMP saturated solution as controls. We prepared TMP-oil 
dispersed in water-ethylene vinyl acetate-transdermal therapeutic system (TMP-O/W-EVA-TTS) 
with microemulsion as reservoir and EVA membrane as release liner; pharmacokinetic and brain 
distribution studies in rats were conducted with TMP transdermal patches as control.
Results: The skin fluxes of  TMP from microemulsions were 8.2- to 26.7-fold and 0.9- to 4.7-fold 
higher than those of  TMP transdermal patch and TMP saturated solution, respectively, and were 
strongly affected by the microemulsion composition. The improvement in TMP solubility as well 
as the skin permeation enhancement effect of microemulsion components contributed mainly 
to transdermal delivery facilitation. In the pharmacokinetic study, the   relative bioavailability 
of  TMP-O/W-EVA-TTS was 350.89% compared with the TMP transdermal patch. Higher 
and more stable TMP contents in rat plasma were obtained after administration of  TMP-O/W-
EVA-TTS than after application of  TMP transdermal patch. In the brain distribution study, 
higher rate and extent of  TMP distribution to brain, and lower rate of  TMP clearance from brain 
were observed after transdermal administration of  TMP-O/W-EVA-TTS than after application 
of  TMP transdermal patch.
Conclusion: The novel transdermal delivery system prepared in this study showed a remarkable 
skin permeation improvement of microemulsion and facilitated its practical application in 
transdermal drug delivery. With this system as a vehicle, a relatively large dose of  TMP could 
enable successful drug delivery via the transdermal route.
Keywords: TMP, microemulsion, EVA membrane, transdermal delivery, pharmacokinetics, 
brain distribution
Introduction
2,3,5,6-tetramethylpyrazine (TMP), an active ingredient isolated in 1957 from the 
traditional medicinal herb Ligusticum wallichii Franch, has been widely used in China to 
treat cardiovascular and cerebrovascular diseases.1,2 In the past 2 decades, TMP has been 
shown to have a beneficial effect on ischemic brain injury in animal experiments and in 
clinical practice.3–5 The mechanism of  TMP neuroprotective effects might be related to anti-
oxidation, reduction of calcium overload, and inhibition of the inflammatory response.6International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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The therapeutic time window of  TMP reducing   cerebral 
ischemia/reperfusion injury in rats was reported to be within a 
4-hour time period post-transient focal stroke.7 It was reported 
recently that following intravenous injection to rats, TMP 
penetrated through the blood–brain barrier within 10 minutes 
but was eliminated rapidly. Two hours after administration, 
plasma level of TMP was undetectable.8,9 Similarly, rapid 
distribution into, and elimination from, brain tissue of  TMP 
were reported after intranasal administration to rats.10,11 Oral 
administration of TMP is known to exhibit extensive first-
pass metabolism, low oral bioavailability (10% to 30%), and 
short biological half-life of 0.5–2 hours, suggesting a possible 
rapid elimination of  TMP from brain.12,13 To maintain 
therapeutic blood levels and subsequent therapeutic levels 
in brain tissue, TMP hydrochloride injection (40 mg/2 mL) 
or TMP phosphate injection (50 mg/2 mL) is diluted with 
250 to 500 mL of isotonic saline or glucose solution and 
intravenously infused for 4–6 hours.14 For maintenance 
therapy, controlled release of  TMP through the transdermal 
route might be meaningful for improving effectiveness as 
well as compliance.
Recently, reservoir type and ethosome-based patch for 
transdermal delivery of  TMP were reported, respectively.15,16 
However, how to enhance the skin permeation for delivering 
TMP to the systemic circulation in therapeutic relevant   levels 
is still a critical issue in the development of transdermal 
formulations, considering the formidable barrier effect of 
the stratum corneum on foreign substances and the relatively 
large dose of  TMP required.
Microemulsion is defined as a dispersion consisting of oil, 
surfactant, cosurfactant, and aqueous phase, which is a single 
optically isotropic and thermodynamically stable liquid 
solution with a droplet diameter usually within the range of 
10–100 nm.17 Microemulsion enhances drug   solubility and 
thermodynamic activity toward the skin, enhances permeation 
activity of its components, is easy to formulate, and fosters the 
system’s thermodynamic stability.18,19 During recent decades 
numerous studies have suggested that microemulsion has the 
potential to increase cutaneous delivery of both hydrophilic 
and lipophilic drugs compared with conventional vehicles. 
However, the practical application of microemulsions as 
transdermal delivery vehicles was limited by their good 
fluidity. Thus, most of the studies were restricted to in vitro 
skin permeation experiments, and few in vivo investigations 
were conducted.20
To facilitate the transdermal delivery of relatively large 
doses of active pharmaceutical ingredients and promote 
the practical application of microemulsions as transdermal 
  delivery vehicles, a novel TMP transdermal therapeutic 
system (TTS) with oil in water (O/W) microemulsion as 
reservoir and ethylene vinyl acetate (EVA) membrane as 
release liner (TMP-O/W-EVA-TTS) was prepared and evalu-
ated mainly through in vitro skin permeation   experiments 
and pharmacokinetic and brain distribution studies in rats 
with TMP transdermal patch (EUDRAGIT® E100 as matrix) 
as control.
Materials and methods
Materials
TMP was obtained from Nanjing Zelang Medical Technology 
Co, Ltd, Nanjing, China. Caprylocaproyl macrogol-8 glycerides 
(Labrasol®) and 1-polyglyceryl-3 dioleate (Plurol® Oleique CC 
497) were donated from Gattefossè, Lyon, France. Isopropyl 
myristate (IPM) was purchased from Shanghai Chemical 
Reagent Corporation, Shanghai, China. EVA membrane with 
19% VA content (3M CotranTM 9728) was obtained from 3M 
Pharmaceuticals, St Paul, MN. Xanthan gum, pharmaceutical 
grade, was purchased from Shandong Fufeng Fermentation 
Co, Ltd, Shandong, China. Polymethacrylates (EUDRAGIT® 
E100) was donated from BASF, Ludwigshafen, Germany. 
Other chemicals are HPLC or analytical grade.
construction of pseudo-ternary phase 
diagram
The water titration method was applied for the phase 
diagram construction. To a certain amount of IPM and 
mixture of Labrasol® (surfactant, S) with Plurol® Oleique 
CC 497 (cosurfactant, CoS), distilled water was added 
dropwise at 25°C under mild magnetic stirring. The 
weight ratio of S to CoS (Km = 3) was fixed at 3:1. The 
weight ratios of IMP to mixture of S with CoS ranged 
from 9.5:0.5, 9:1, 8.5:1.5, 8:2, 7.5:2.5, 7:3, 6:4, 5:5, 4:6, 
3:7, 2:8, to 1:9. The system with low viscosity and clear 
appearance was considered to be microemulsion. The 
critical points between microemulsion region and other 
phase regions were determined when the appearance of 
the system changed from clear to turbid, and vice versa. 
The microemulsion regions were defined as O/W or O/W 
type according to oil and water weight ratios. The obtained 
phase diagram is shown in Figure 1.
Formulation optimization
To optimize microemulsion formulation, a 2-factor, 
6-level uniform experimental design was employed. International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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The content of oil (X1), weight percentage of surfactant 
and cosurfactant mixture, Km = 3, (X2), and TMP skin 
flux in vitro (Y1) were selected as factors and response, 
respectively.
Since O/W microemulsions were reported to provide 
significantly greater fluxes for both hydrophobic and hydro-
philic drugs, six formulations were selected in this region, 
and six runs were conducted.21 The experimental design and 
the compositions of the tested formulations are presented in 
Tables 1 and 2, respectively.
The data from the skin permeation experiments in 
vitro were fitted to a second-order polynomial model. Data 
fitting was also undertaken with equilibrium   solubility 
of TMP in microemulsions (Y2) as response, since 
solubility improvement was reported to possibly play a 
major role in enhancing drug transdermal delivery by 
microemulsions.22,23
Formulation 6 with TMP loading of 0.6%, 1.0%, and 
2.0% (W/W) was prepared. The influence of  TMP loading 
on skin flux in vitro was evaluated.
characterization of the prepared 
microemulsions
The viscosity of the prepared microemulsions was mea-
sured using a Brookfield DV-II + digital viscometer (Brook-
field Engineering Laboratories Inc, MA, USA) with a No. 
1 rotor set at 100 rpm, and the average droplet sizes were 
measured with photo-correlation spectroscopy through a 
Nano ZS90 Zetasizer (Malvern Instruments Ltd, Worces-
tershire, UK). The morphology of TMP-loaded micro-
emulsion (formulation 6) was observed with transmission 
electron microscopy (TEM) (JEM-1230; JEOL, Tokyo, 
Japan). Samples were placed on a film-coated copper grid 
and allowed to stand for 2 minutes and excess fluid was 
removed with filter paper.
The equilibrium solubility of  TMP in formulations 1 to 6 
was determined. First, blank microemulsions were prepared 
by adding distilled water dropwise to the mixture of IPM, 
Labrasol®, and Plurol® Oleique CC 497 under mild magnetic 
stirring at room temperature. Then, excess TMP was added 
to each blank microemulsion. The obtained TMP-loaded 
microemulsions were sealed and kept under mild magnetic 
stirring at room temperature for 72 hours. After centrifugation 
at 10,000 rpm for 10 minutes, TMP concentrations in the 
supernatants were measured by HPLC after suitable dilution 
with methanol.
skin permeation experiments in vitro
Franz type diffusion cells were applied for the skin pen-
etration experiments. The effective penetration area was 
1.7 cm2 and the receptor compartment volume was 16 cm3. 
Fresh excised abdominal skins of male Sprague-Dawley 
rats were used as a barrier membrane. To the donor com-
partments, 3 mL TMP saturated solution or TMP-loaded 
microemulsion was added, and the compartments were 
sealed with parafilm. TMP transdermal patches with 
TMP loading of 10 mg and effective penetration area 
of 6 cm2 were prepared and used as control. The TMP 
  transdermal patches were attached to the skins, trimmed, 
and fixed together with donor compartments. To ensure 
sink   conditions, 10% ethanol in normal saline (v/v) was 
used as receptor medium.
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Figure 1 Pseudo-ternary phase diagram of microemulsion composed of isopropyl 
myristate, surfactant (Labrasol®) and cosurfactant (Plurol® Oleique cc 497), Km = 3:1, 
and water. (A) O/W microemulsion zone; (B) and (C) W/O microemulsion zones.
Abbreviations: O/W, oil in water; W/O, water in oil.
Table  1  Uniform  experimental  design  for  microemulsion 
formulation optimization
Experiment Factors
X1 (weight ratio  
of oil, %)
X2 (weight ratio  
of the mixture of S  
and CoS, Km = 3, %)
1 6.0 38.0
2 7.0 56.0
3 8.0 32.0
4 9.0 50.0
5 10.0 30.0
6 11.0 44.0International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Samples of 1.0 mL were taken from receptor compartments 
at predetermined time intervals, and replenished with blank 
medium of the same volume at 32°C. TMP concentrations 
in obtained samples were determined by HPLC.
The cumulative amounts of TMP permeated through 
excised rat skin were calculated by the equation:
  Qs V
S C
V
S
C
n1
n1
=×
−
−
ni
i + ∑
where Cn is the TMP concentration in the receptor medium 
at each sampling time, Ci is the drug concentration of the 
sample, and V and Vi are the volumes of the receptor medium 
and the sample, respectively. S is the effective diffusion area 
(S = 1.7 cm2). The cumulative amount of  TMP was plotted 
as a function of time. The permeation rate of  TMP as steady 
state (Js, µg/cm2/h) through rat skin was calculated from the 
slope of the linear portion of the cumulative amount per unit 
area versus time plot.
Drug-release experiments in vitro
A release experiment in vitro of TMP from formulation 
6 at TMP loading of 1.0% (W/W) was undertaken. The 
experimental conditions were the same as those for the skin 
permeation experiments in vitro, except for the replacement 
of rat skins by the EVA membranes as permeation barriers.
Fabrication of   TMP-O/W-eVA-TTs
TMP-O/W-EVA-TTSs were fabricated with microemulsion as 
reservoir and EVA membrane as release liner. Microemulsion 
was prepared according to formulation 6, with TMP loading 
being 1.0% (w/w). To facilitate the preparation of  TMP-O/W-
EVA-TTSs, 0.5% (w/w) of xanthan gum was added to the 
microemulsion. The TMP loading and the effective skin 
permeation area of  TMP-O/W-EVA-TTSs were 10 mg and 
6 cm2, respectively.
TMP transdermal patches with the same drug   loading and 
effective permeation area as those of  TMP-O/W-EVA-TTSs 
were prepared and employed as control in the pharmacokinetic 
and brain distribution studies in rats.
Pharmacokinetic study
Male Sprague-Dawley rats (220–240 g), provided by Shanghai 
University of TCM Animal Center (Shanghai, China), were 
randomly divided into TMP-O/W-EVA-TTS and TMP 
transdermal patch groups (n = 6). TMP-O/W-EVA-TTS was 
administered transdermally as a single dose to the abdomi-
nal area of each rat in the TMP-O/W-EVA-TTS group after 
carefully shaving the hair. Similarly, TMP transdermal patch 
was administered to each rat in the TMP-O/W-EVA-TTS 
group.
After the administration, 300-µL blood samples were 
withdrawn from eye venous plexus and collected into 
heparinized tubes at 0, 1, 2, 3, 4, 8, 12, and 24 hours from 
rats in each group. Plasma samples were separated by imme-
diate centrifugation at 6000 rpm for 5 minutes, and stored 
at -70°C until analysis.
To a volume of 150 µL plasma sample, 15 µL of doxofyl-
line as internal standard, NaOH solution (1 N), and metha-
nol were added consecutively. The obtained mixture was 
extracted twice with N-hexane and chloroform (2:1, v/v). At 
each extraction, a total of 450 µL N-hexane and chloroform 
was added and mixed with a vortex mixer for 3 minutes. After 
centrifugation at 15,000 rpm at 4°C for 10 minutes, the super-
natants from each plasma sample were combined and 15 µL 
of HCl in methanol solution (1 N) was added. The solvent 
was evaporated to dryness under gentle nitrogen stream. Each 
residue was reconstituted with 50 µL of methanol before the 
determination of  TMP content by HPLC.
The measurements of  TMP concentrations in rat plasma 
were carried out with a SHIMADAZU HPLC system 
equipped with a UV detector, an autosampler, and a reverse 
phase Dikma Platisil C18 column. The mobile phase was com-
posed of methanol and ammonium chloride buffer (45:55, 
v/v), and the pH value of the mobile phase was adjusted 
to 10.0. The flow rate was 1.0 mL/minute. The detection 
Table 2 compositions and drug loadings of formulations 1 to 6 of microemulsions
Formulation Weight fractions of components (%, w/w) TMP loading  
(%, w/w)
Azone  
(%, w/w) Labrasol® Plurol® Oleique CC IPM Water
1 28.5 9.5 6.0 56.0
2 42.0 14.0 7.0 37.0
3 24.0 8.0 8.0 60.0 2.0 1.0
4 37.5 12.5 9.0 41.0
5 22.5 7.5 10.0 60.0
6 33.0 11.0 11.0 45.0
Abbreviations: IPM, isopropyl myristate; TMP, 2,3,5,6-tetramethylpyrazine.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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wavelength was set at 280 nm, the column temperature was 
set at 35°C, and the injection volume was 20 µL.
Brain distribution study
The animal grouping and administration were the same as 
those of pharmacokinetic study, except that 21 instead of 
six rats were used in each group. At 0, 2, 4, 8, 12, 16, and 
24 hours after the administration, rats (n = 3 for each time 
point) in each group were sacrificed, and a brain sample 
from each rat was isolated, rinsed thoroughly with normal 
saline, and weighed after drying with filter paper. To each 
tube containing 1 brain sample, normal saline was added 
at a weight ratio of 2:1. After homogenation for 5 minutes 
with a hand-held tissue homogenizer in an ice water bath 
and centrifugation at 10,000 rpm for 5 minutes, brain 
homogenate samples were obtained and stored at -70°C 
until analysis.
Brain homogenate samples were prepared by the same 
procedure as plasma samples except that 100 µL of dox-
ofylline, NaOH solution (1 N), and methanol were added 
to 1.0 mL brain homogenate sample, and a total of 3.0 mL 
N-hexane and chloroform was added at each time of extrac-
tion, and 100 µL of HCl in methanol solution (1 N) was added 
to the supernatant from each brain homogenate sample. The 
HPLC conditions for TMP contents measurement in rat brain 
homogenates were the same as those for TMP concentration 
determination in rat plasma.
Data analysis
Non-compartment pharmacokinetic analysis of  TMP plasma 
concentrations versus time data were conducted using 
BAPP2.0 (Bioavailability program package 2.0, Center for 
Metabolism and Pharmacokinetics, China Pharmaceutical 
University, Nanjing, China).
Results and discussion
characterization of the prepared 
microemulsions
The mean droplet sizes of the prepared microemulsions 
ranged from 42.74 to 95.04 nm, and polydispersity index 
ranged from 0.251 to 0.397, suggesting small nanosized 
droplets with relative uniform droplet sizes were obtained 
following formulations 1 to 6 (Table 3). The microemulsion 
droplets obtained were spherical and relatively even in size 
(Figure 2). A trend of viscosity increase was observed when 
the contents of Labrasol® (surfactant) in the formulations 
were .37.5%.
Formulation optimization
The skin permeation profiles of formulations 1 to 6 of 
microemulsions compared with TMP transdermal patch and 
TMP saturated solution are shown in Figure 3, and the skin 
permeation parameters of TMP are presented in Table 3. 
An obvious enhancement in skin permeability of  TMP was 
observed by the application of all microemulsions compared 
with the TMP transdermal patch. The highest skin flux 
Table 3 characteristics of formulation 1 to formulation 6 and skin permeation parameters of TMP
Formulation Characteristics of microemulsions Skin permeation   
parameter
Mean droplet 
size (nm)
PDI Viscosity  
(mPa⋅S)
TMP solubility  
(mg/mL)
Flux  
(mg/cm2/h)
1 51.47 ± 0.25 0.352 ± 0.015 34.0 ± 0.4 4.13 0.164 ± 0.022
2 95.04 ± 1.30 0.251 ± 0.015 53.2 ± 0.5 7.07 0.139 ± 0.004
3 45.02 ± 0.37 0.329 ± 0.003 30.2 ± 1.1 6.07 0.087 ± 0.012
4 78.21 ± 1.20 0.274 ± 0.004 45.0 ± 0.6 4.93 0.183 ± 0.019
5 42.74 ± 0.13 0.375 ± 0.011 30.2 ± 0.5 5.93 0.191 ± 0.023
6 66.64 ± 0.18 0.397 ± 0.002 33.3 ± 1.6 9.88 0.263 ± 0.027
TMP transdermal patch – – – – 0.009 ± 0.0007
TMP saturated solution – – – 1.90 0.046 ± 0.005
Abbreviations: PDI, polydispersity index; TMP, 2,3,5,6-tetramethylpyrazine.
Figure  2  Transmission  electron  microscopy  of  tetramethylpyrazine-loaded 
microemulsion (formulation 6).International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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of  TMP (0.263 ± 0.027 mg/cm2/h) was obtained following 
the application of formulation 6. The skin fluxes of TMP 
from microemulsions were 8.2- to 26.7-fold higher than 
from TMP transdermal patch. This result might be due to the 
much higher diffusion rates of  TMP from microemulsions as 
liquid medium than that from TMP transdermal patch with 
pressure-sensitive adhesive as solid matrix. Similarly, the skin 
fluxes of  TMP from microemulsions were 0.9- to 4.7-fold 
higher than those from TMP saturated solution.
The permeation profiles of microemulsions followed zero 
order release kinetics. The possible explanation is that the sur-
factant and cosurfactant may exist in each phase of the micro-
emulsion, so that active ingredient can be partly solubilized in 
external phase, and the depletion of active ingredient in external 
phase because of permeation into the skin can be supplemented 
by the release of active ingredient from internal phase. Then the 
zero order release kinetics and sustained, controlled, prolonged 
delivery of active ingredient were obtained.24
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Figure 3 In vitro skin permeation profiles of TMP from formulations 1 to 6 of microemulsions, TMP loading was 2% (w/w), with TMP transdermal patch and TMP saturated 
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The second-order polynomial equations with TMP skin 
flux in vitro (Y1), and equilibrium solubility of  TMP in 
microemulsions (Y2), respectively, content of IPM (X1), and 
weight percentage of surfactant and cosurfactant mixture 
(S/Cos), Km = 3, (X2) as factors were as follows:
 Y 1 =     0.866 - 20.295X1 + 128.707X1
2 
+ 0.025X2
2 + 1.663X1X2 (R = 0.952)
 Y 2 =   16.199 - 362.690X1 + 2977.834X1
2  
+ 23.617X2
2 - 162.797X1X2 (R = 0.808)
The second-order polynomial equations show that 
Y1 was better correlated than Y2 with X1 and X2. This 
might be due to the skin permeation enhancement effect 
of microemulsion components. IPM was reported to be 
an effective penetration enhancer, and the surfactant and 
cosurfactant in the microemulsions might reduce the 
diffusional barrier of the stratum corneum by acting as 
permeation enhancers.25,26
To find out the influence of microemulsion composition 
on the skin permeation behavior of  TMP, grid searches over 
the whole experimental region were conducted under the 
guidance of visual basic programs on the basis of second-
order polynomial equations mentioned above. According to 
the grid searches, an increase of skin flux and TMP solubility 
in microemulsions were observed with the increase of IPM 
content as well as the weight fraction of S/CoS. The chang-
ing IPM content showed greater influence on TMP skin flux, 
which was no more than 0.18 µg/cm2/h, when IMP content 
was ,9% (w/w). Thus, the improvement in TMP solubil-
ity as well as the skin permeation enhancement effect of 
microemulsion components contributed mainly to transder-
mal delivery facilitation. This result was in agreement with 
previous work.27
According to earlier reports, drug flux decrease was 
observed with the increase in amount of surfactant in 
microemulsions,28,29 possibly because of a decreased ther-
modynamic activity of the drug in microemulsion at higher 
surfactant concentrations. Another possibility was that drug 
diffusion through the double layer microemulsion might be a 
rate-determining step, as viscosity plays an important role in 
controlling the drug release into the receptor.30 However, in 
this study, the skin flux increase was observed with the rise 
in the weight fraction of S/CoS. The first mechanism might 
be because the viscosity of the systems prepared in this study 
did not increase as much with increasing amount of surfactant 
as that reported previously. The second possibility was that 
medium-weight fractions of surfactant ranging from 22.5% to 
42.0% were chosen for this study. In addition, the mixture of 
Table 4 skin permeation parameters in vitro and characteristics of formulation 6 with different drug loadings
Drug loading (%, w/w) Saturated amount of TMP  
in the donor compartment (mg)
Residue amount of TMP in the  
donor compartment after 24 h (mg)
Skin flux of TMP   
(mg/cm2/h)
0.6 29.64 15.72 ± 1.24 0.056 ± 0.007
1.0 29.64 25.86 ± 3.58 0.103 ± 0.014
2.0 29.64 49.10 ± 4.96 0.263 ± 0.027
Abbreviation: TMP, 2,3,5,6-tetramethylpyrazine.
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surfactant and cosurfactant, but not surfactant alone, served 
as a factor in the experiments of uniform design conducted 
in this study.
The permeation rate of  TMP was almost proportional to 
drug loading (Figure 4). To give a possible explanation of 
this phenomenon, the saturated amount of  TMP in the donor 
compartment and the residue amount of  TMP after 24 hours 
were calculated (Table 4). The reduction of  TMP skin flux 
with decrease in TMP loading might be due to the depletion 
of  TMP in the donor compartment and subsequent decline 
of driving concentration. However, in consideration of the 
physical instability when the drug loading was 2.0%, namely 
crystallization of  TMP during storage, the final loading 
of  TMP in formulation 6 was 1.0%.
A higher release flux of  TMP than skin permeation flux 
was observed (Figure 4), indicating that the rate-limiting step 
in TMP skin permeation process was its permeation through 
the skin rather than its release from the vehicle. This result 
is in agreement with a previous report.31
Pharmacokinetic and brain distribution 
studies
Mean rat plasma concentrations versus time profiles and 
the pharmacokinetic parameters of  TMP are shown in 
Figure 5 and Table 5, respectively. Within 4 hours after 
the administration, TMP-O/W-EVA-TTS and TMP trans-
dermal patch showed comparable plasma concentrations. 
However, after that, TMP-O/W-EVA-TTS showed an   
obvious increase of  TMP contents in plasma, Cmax of  TMP 
was reached in 12 hours, and high levels of  TMP were 
maintained in 24 hours. In contrast, TMP transdermal patch 
showed considerable reduction of  TMP contents in plasma, 
and low levels of  TMP were observed from 8 to 24 hours 
after the administration. The overall mean value of AUC0-t 
of  TMP-O/W-EVA-TTS was 2.5 times higher than that 
of  TMP-O/W-EVA-TTS (P , 0.01). The subsequent rela-
tive bioavailability of  TMP-O/W-EVA-TTS was 350.89%. 
Similarly, significantly prolonged (P , 0.01) MRT and 
reduced (P , 0.05) Cl of  TMP-O/W-EVA-TTS were   
observed.
TMP-O/W-EVA-TTS showed higher TMP contents 
than TMP transdermal patch during the whole experimental 
period, namely within 24 hours after administration 
(Figure 6). This result suggests the higher distribution rate 
and extent of TMP to brain, and lower clearance of TMP 
from brain following the transdermal administration of 
TMP-O/W-EVA-TTS, than from administration of TMP 
transdermal patch.
Table 5 Pharmacokinetic parameters of TMP after a single-dose 
transdermal  administration  of  TMP-O/W-eVA-TTs  (10  mg  of 
TMP in 6 cm2) to each rat in group A (n = 6) and TMP transdermal 
patch (10 mg of TMP in 6 cm2) to each rat in group B (n = 6)
Parameters TMP-O/W-EVA-TTS TMP transdermal 
patch
cmax (µg/mL) 0.49 ± 0.09   0.29 ± 0.07
Tmax (h) 12.00   2.67 ± 0.58
AUc (h*µg/mL) 9.0495 ± 1.2368** 2.579 ± 0.723
MrT (h) 12.1939 ± 0.3712** 7.886 ± 0.351
cl (L/h) 0.676 ± 0.207* 3.324 ± 0.997
relative  
bioavailability (%)
350.89
Notes: * and ** represent P , 0.05 and P , 0.01, respectively, compared with TMP 
transdermal patch.
Abbreviations:  AUc, area under the curve; cl, clearance; MrT, mean residence 
time; TMP, 2,3,5,6-tetramethylpyrazine; TMP-O/W-eVA-TTs,  tetramethylpyrazine- 
oil dispersed in water-ethylene vinyl acetate-transdermal therapeutic system.
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Figure 6 Mean concentrations of TMP in rat brain homogenate versus time profiles from TMP-O/W-EVA-TTS and TMP transdermal patch.
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Conclusion
The novel transdermal delivery system prepared in this 
study showed a remarkably improved skin permeation of 
microemulsion and facilitated its practical application in 
transdermal drug delivery. With this system as a vehicle, a 
relatively large dose of TMP could enable successful drug 
delivery via the transdermal route.
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